NASDAQ$BBIO
Bridgebio Pharma Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results and business update for the second quarter of 2022.
BridgeBio Pharma reported positive proof-of-concept data in three key programs and five additional early-to-mid-stage pipeline programs. They entered an exclusive license agreement with Bristol Myers Squibb for BBP-398 and announced the sale of a Priority Review Voucher. The company ended the quarter with $688.6 million in cash, cash equivalents and marketable securities.
- Reported positive interim Phase 2 data for infigratinib in achondroplasia.
- Reported positive Phase 2 data for encaleret in autosomal dominant hypocalcemia type 1 (ADH1).
- Entered into exclusive license agreement with Bristol Myers Squibb for BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology.
- Ended quarter with $688.6 million in cash, cash equivalents and marketable securities, providing financial runway into 2024.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$73.7M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio expects operating expenses and cash burn to continue to decline meaningfully in the third and fourth quarters as restructuring charges decline and anticipated additional business development activity allows further decrease from this baseline.
Tailwinds
- Positive interim Phase 2 data for infigratinib in achondroplasia
- Positive Phase 2 data for encaleret in ADH1
- Selected a next-generation KRAS G12C dual inhibitor development candidate
- Positive data for five early-to-mid-stage genetic disease programs in pipeline
- Received positive opinion from CHMP for NULIBRY
Headwinds
- Restructuring, impairment and related charges
- Net loss attributable to common stockholders of BridgeBio
- COVID-19 pandemic impact on clinical enrollment and trial commencement activities
- Potential delays in regulatory review
- Manufacturing and supply chain interruptions
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro